

# Chapter 141

## The Neurofibromatoses

Robert Listerick & Joel Charrow

### REFERENCES

1. Upadhyaya M et al: Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. *Hum Genet* **102**(5):591-597, 1998
2. Clementi M et al: Neurofibromatosis-1: A maximum likelihood estimation of mutation rate. *Hum Genet* **84**(2):116-118, 1990
3. Rubin JB, Gutmann DH: Neurofibromatosis type 1 - A model for nervous system tumour formation? *Nat Rev Cancer* **5**(7):557-564, 2005
4. Dasgupta B, Gutmann DH: Neurofibromatosis 1: Closing the GAP between mice and men. *Curr Opin Genet Dev* **13**(1):20-27, 2003
5. Dasgupta B et al: Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. *Cancer Res* **65**(1):236-245, 2005
6. Costa RM, Silva AJ: Mouse models of neurofibromatosis type I: Bridging the GAP. *Trends Mol Med* **9**(1):19-23, 2003
7. Li C et al: Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. *Brain Res Dev Brain Res* **130**(2):231-248, 2001
8. Zhu Y et al: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. *Science* **296**(5569):920-922, 2002
9. Yang FC et al: Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1 +/- mast cells. *J Clin Invest* **112**(12):1851-1861, 2003
10. Bajenaru ML et al: Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. *Cancer Res* **63**(24):8573-8577, 2003
11. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. *Arch Neurol* **45**(5):575-578, 1988
12. Messian L et al: Clinical and mutational spectrum of neurofibromatosis type-1 like syndrome. *JAMA* **302**:2111-2118, 2009
13. Listerick R, Charrow J: Neurofibromatosis-1 in childhood. *Adv Dermatol* **20**:75-115, 2004
14. Obringer AC, Meadows AT, Zackai EH: The diagnosis of neurofibromatosis-1 in the child under the age of 6 years. *Am J Dis Child* **143**(6):717-719, 1989
15. Woodruff JM: Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. *Am J Med Genet* **89**(1):23-30, 1999
16. Korf BR: Plexiform neurofibromas. *Am J Med Genet* **89**(1):31-37, 1999
17. Vogel KS et al: Mouse tumor model for neurofibromatosis type 1. *Science* **286**(5447):2176-2179, 1999
18. Cichowski K et al: Mouse models of tumor development in neurofibromatosis type 1. *Science* **286**(5447):2172-2176, 1999
19. Listerick R et al: Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. *J Pediatr* **125**(1):63-66, 1994
20. Listerick R et al: Optic gliomas in children with neurofibromatosis type 1. *J Pediatr* **114**(5):788-792, 1989
21. Habiby R et al: Precocious puberty in children with neurofibromatosis type 1. *J Pediatr* **126**(3):364-367, 1995
22. Vitale MG, Guha A, Skaggs DL: Orthopaedic manifestations of neurofibromatosis in children: An update. *Clin Orthop* (401):107-118, 2002
23. Listerick R, Charrow J, Gutmann DH: Intracranial gliomas in neurofibromatosis type 1. *Am J Med Genet* **89**(1):38-44, 1999
24. Listerick R et al: Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. *Ann Neurol* **41**(2):143-149, 1997
25. Wolkenstein P et al: Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. *Arch Dermatol* **132**(11):1333-1336, 1996
26. Tonggard JH et al: CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. *Neurology* **50**(6):1755-1760, 1998

27. Cai W et al: Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination of whole body MR images. *Radiology* **250**:665-673, 2009
28. Listernick R, Charrow J: Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood. *Am J Med Genet* **127**(3):221-223, 2004
29. Sorensen SA, Mulvihill JJ, Nielsen A: Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. *N Engl J Med* **314**(16):1010-1015, 1986
30. Matsui I et al: Neurofibromatosis type 1 and childhood cancer. *Cancer* **72**(9):2746-2754, 1993
31. Evans DG et al: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* **39**(5):311-314, 2002
32. Ferner RE, Gutmann DH: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. *Cancer Res* **62**(5):1573-1577, 2002
33. Ferner RE et al: Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. *J Neurol Neurosurg Psychiatry* **68**(3):353-357, 2000
34. Walther MM et al: von Recklinghausen's disease and pheochromocytomas. *J Urol* **162**(5):1582-1586, 1999
35. Gutmann DH et al: Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. *Genes Chromosomes Cancer* **13**(2):104-109, 1995
36. Xu W et al: Loss of NF1 alleles in pheochromocytomas from patients with type I neurofibromatosis. *Genes Chromosomes Cancer* **4**(4):337-342, 1992
37. Stiller CA, Chessells JM, Fitchett M: Neurofibromatosis and childhood leukaemia/lymphoma: A population-based UKCCSG study. *Br J Cancer* **70**(5):969-972, 1994
38. Side L et al: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. *N Engl J Med* **336**(24):1713-1720, 1997
39. Bader JL: Neurofibromatosis and cancer. *Ann NY Acad Sci* **486**:57-65, 1986
40. Cooper PH et al: Association of juvenile xanthogranuloma with juvenile myeloid leukemia. *Arch Dermatol* **120**(3):371-375, 1984
41. Oguzkan S et al: Two neurofibromatosis type 1 cases associated with rhabdomyosarcoma of bladder, one with a large deletion in the NF1 gene. *Cancer Genet Cytogenet* **164**(2):159-163, 2006
42. Sung L et al: Neurofibromatosis in children with Rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma study IV. *J Pediatr* **144**(5):666-668, 2004
43. Takazawa Y et al: Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). *Am J Surg Pathol* **29**(6):755-763, 2005
44. Hamilton SJ, Friedman JM: Insights into the pathogenesis of neurofibromatosis 1 vasculopathy [see comment]. *Clin Genet* **58**(5):341-344, 2000
45. Kurien A, John PR, Milford DV: Hypertension secondary to progressive vascular neurofibromatosis. *Arch Dis Child* **76**(5):454-455, 1997
46. Fossali E et al: Renovascular disease and hypertension in children with neurofibromatosis. *Pediatr Nephrol* **14**(8-9):806-810, 2000
47. DiPaolo DP et al: Neurofibromatosis type 1: Pathologic substrate of high-signal-intensity foci in the brain. *Radiology* **195**(3):721-724, 1995
48. Joy P et al: Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. *Dev Med Child Neurol* **37**(10):906-914, 1995
49. Ferner RE, Hughes RA, Weinman J: Intellectual impairment in neurofibromatosis 1. *J Neurol Sci* **138**(1-2):125-133, 1996
50. North K, Hyman S, Barton B: Cognitive deficits in neurofibromatosis 1. *J Child Neurol* **17**(8):605-612, 2002
51. Hyman SL, Shores A, North KN: The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. *Neurology* **65**(7):1037-1044, 2005
52. Alora MB, Arndt KA: Treatment of a cafe-au-lait macule with the erbium:YAG laser. *J Am Acad Dermatol* **45**(4):566-568, 2001
53. Somyos K et al: Copper vapour laser treatment of cafe-au-lait macules. *Br J Dermatol* **135**(6):964-968, 1996
54. Riccardi VM: A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching [see comment]. *Arch Dermatol* **129**(5):577-581, 1993
55. Moreno JC et al: Carbon dioxide laser for removal of multiple cutaneous neurofibromas. *Br J Dermatol* **144**(5):1096-1098, 2001

56. Yang FC et al: Nf1-dependent tumors require a microenvironment containing Nf1 +/- and c-kit-dependent bone marrow. *Cell* **135**:437-448, 2008
57. Listernick R et al: Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1. *J Neurooncol* **45**(2):185-190, 1999
58. Evans DG et al: Management of the patient and family with neurofibromatosis 2: A consensus conference statement. *Br J Neurosurg* **19**(1):5-12, 2005
59. Listernick R, Mancini AJ, Charrow J: Segmental neurofibromatosis in childhood. *Am J Med Genet* **121**(2):132-135, 2003
60. Ruggieri M, Huson SM: The clinical and diagnostic implications of mosaicism in the neurofibromatoses. *Neurology* **56**(11):1433-1443, 2001
61. Tinschert S et al: Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. *Eur J Hum Genet* **8**(6):455-459, 2000
62. De Luca A et al: NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. *Am J Hum Genet* **77**(6):1092-1101, 2005
63. Baser ME, Friedman JM, Evans DG: Increasing the specificity of diagnostic criteria for schwannomatosis. *Neurology* **66**(5):730-732, 2006
64. MacCollin M et al: Diagnostic criteria for schwannomatosis. *Neurology* **64**(11):1838-1845, 2005
65. Boyd C et al: Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. *Clin Genet* **74**:358-366, 2008

